thromboDx BV is a molecular diagnostics company that develops and commercialises blood-based diagnostics through its proprietary platelet-powered technology platform and has its offices in Amsterdam, The Netherlands. The technology platform addresses the need for an easily accessible, minimally invasive source for high quality disease-specific nucleic acids in several markets. thromboDx BV targets 3 major markets: Cancer Diagnostics, Infectious Disease Monitoring, and Prenatal Testing.
As a spin out from the VU University Medical Center (VUmc), thromboDx BV is embedded in an excellent scientific and clinical infrastructure that allows rapid access to patient cohorts and clinical studies. Medical diagnostics and oncology are key focus points of VUmc and the company has access to top end infrastructure and labs for its scientific work. Collaborations have been established with several research groups at VUmc, the University of Umea in Sweden and with Harvard Medical School and Massachusetts General Hospital in Boston.
thromboDX has been acquired by Illumina in 2016